TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04049786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam 2 mg for CYP3A4 phenotyping
Description: Midazolam is being used as probe drug to evaluate CYP3A4 activity. Single-dose of midazolam 2 mg are being administrated intravenous.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Genotyping
Description: Patients are being genotyped for the main SNP on CYP2C9, ABCB1, SLCO1B1 and CYP2D6 genes using blood samples

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Genotyping
Description: Patients are being genotyped for the main SNP on CYP2C9, ABCB1, SLCO1B1 and CYP2D6 genes using blood samples
Study: NCT03842722

Intervention type: DEVICE
Intervention: Protoporphyrin IX - Triplet State Lifetime Technique
Description: Protoporphyrin IX - Triplet State Lifetime Technique is a way to measure mitochondrial oxygen tension in a non-invasive way at bedside.
Study: NCT03068533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 8% L-Arginine/calcium carbonate containing toothpaste
Description: use of 8% L-Arginine/calcium carbonate containing toothpaste to relieve hypersensitivity
Study: NCT04049786

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Genotyping
Description: Patients are being genotyped for the main SNP on CYP2C9, ABCB1, SLCO1B1 and CYP2D6 genes using blood samples

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Genotyping
Description: Patients are being genotyped for the main SNP on CYP2C9, ABCB1, SLCO1B1 and CYP2D6 genes using blood samples

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Genotyping
Description: Patients are being genotyped for the main SNP on CYP2C9, ABCB1, SLCO1B1 and CYP2D6 genes using blood samples

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Genotyping
Description: Patients are being genotyped for the main SNP on CYP2C9, ABCB1, SLCO1B1 and CYP2D6 genes using blood samples
Study: NCT01804400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00999102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Metoprolol 50 mg, Metoprolol 100 mg,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Metoprolol 50 mg, Metoprolol 100 mg,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Nebivolol 5 mg, Nebivolol 10 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Nebivolol 5 mg, Nebivolol 10 mg.
Study: NCT02310698

Intervention type: DEVICE
Intervention: contrast enhanced digital mammography (CEDM)

Intervention type: DEVICE
Intervention: whole breast screening ultrasound (WBUS)
Study: NCT03135600

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure
Description: Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk/run on the treadmill in barefoot at 4/6km/h.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure
Description: Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk/run on the treadmill in barefoot at 4/6km/h.
Study: NCT02431637

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Administration of the malaria inoculum
Description: Each participant in the cohort will be inoculated on Day 0 with \~2,800 viable parasites of Plasmodium falciparum-infected human erythrocytes (BSPC) administered intravenously. The threshold for commencement of treatment will be when PCR quantification of all participants is ≥ 5,000 parasites/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperaquine Phosphate 480 mg
Description: When PCR quantification of all participants is ≥ 5,000 parasites/mL, participants will receive a single dose of 480 mg Piperaquine Phosphate
Study: NCT04613648

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: Ultrasonographic imaging of the shoulder

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: Ultrasonographic imaging of the shoulder

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: Ultrasonographic imaging of the shoulder
Study: NCT01352793

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rLP2086 vaccine
Description: 120 mcg, 3 doses, at month 0, 2, and 6.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: control
Description: HAVRIX: 720 EL.U. or 1440 EL.Ul, 2 doses, at month 0 and 6. Placebo: normal saline injection, 1 dose, at month 2.
Study: NCT03000608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAN021 Serum
Description: SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
Study: NCT03068533

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: use of strontium acetate toothpaste
Description: use of strontium acetate toothpaste to relieve hypersensitivity
Study: NCT01190514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desvenlafaxine succinate sustained release
Description: Two tablets of 25 mg, single administration, under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desvenlafaxine succinate sustained release
Description: One tablet of 50 mg, single administration, under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desvenlafaxine succinate sustained release
Description: Two tablets of 25 mg, single administration, under fast condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desvenlafaxine succinate sustained release
Description: One tablet of 50 mg, single administration, under fast condition
Study: NCT04628819

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Babybiane Imedia or placebo
Description: Both the investigational product as well as the placebo will be administered once daily, diluted in a nursing bottle or a glass of water or cold milk, or mixed with a food suitable for the child. It may be diluted in oral rehydration solution and is to be taken preferably before a meal. Both preparations (BABYBIANE® Imedia and placebo) will have similar consistency and taste. A supplementation unit will contain 7 packs of either products, one per supplementation day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Babybiane Imedia or placebo
Description: Both the investigational product as well as the placebo will be administered once daily, diluted in a nursing bottle or a glass of water or cold milk, or mixed with a food suitable for the child. It may be diluted in oral rehydration solution and is to be taken preferably before a meal. Both preparations (BABYBIANE® Imedia and placebo) will have similar consistency and taste. A supplementation unit will contain 7 packs of either products, one per supplementation day.
Study: NCT01327859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prior Donepezil 5mg
Description: Received 5 mg donepezil once daily during the preceding double-blind study, E2020-G000-316. Received open-label 5 or 10 mg donepezil during the present study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prior Donzepezil 10mg
Description: Received 10 mg donepezil once daily during the preceding double-blind study, E2020-G000-316 . Received open-label 5 or 10 mg donepezil during the present study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prior Placebo
Description: Received placebo once daily during the preceding double-blind study, E2020-G000-316. Received open-label 5 or 10 mg donepezil during the present study.
Study: NCT02054988

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: caffeine
Description: After 5 day coffee wash-out period, patients were randomly assigned to caffeine for 10 days. At baseline: 2 cups of coffee consecutively after 5 hour by clopidogrel or prasugrel intake. Afterwards, 3 cups of coffee daily for 10 days.~Platelet reactivity (expressed as P2Y(12) reaction units (PRU) by the point-of-care VerifyNow assay \[Accumetrics, San Diego, California\]) was measured at baseline and after 10-days of coffee intake.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: not caffeine
Description: evaluate the platelet reactivity after 10 days of no caffeine intake
Study: NCT04257591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hamstring strengthening
Description: A progressive and individualized hamstring strengthening protocol
Study: NCT01597453

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle counseling
Description: Ultrasound examinations of carotid arteries, aorta abdominalis, femoral arteries and lifestyle counseling
Study: NCT04390022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: Single dose of STROMECTOL® tablets at 400mcg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will not match ivermectin but they will be administered by staff not involved in the clinical care.
Study: NCT02619149

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin-tazobactam combination product
Description: Piperacillin-Tazobactam (extended-spectrum, beta-lactamase inhibitor) iv peroperatively as prophylaxis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Saline iv as placebo control
Study: NCT02068209

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: patients will receive Tramadol 50mg orally 1 hour before outpatient hysteroscopy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients will receive a placebo 1 hour before outpatient hysteroscopy
Study: NCT03525288

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PSMA -PET/CT simulation
Description: * PET/CT simulation.~* If no additional lesions detected: RT as planned per standard care.~* If PSMA-PET/CT imaging consistent with oligometastases (1-5 lesions): all lesions must be treated with definitive RT.~* If PSMA-PET/CT imaging consistent with widely metastatic disease (\>5 lesions): treatment of all detected disease with RT is not recommended, but treatment of the primary site as initially planned is encouraged.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard-care simulation
Description: No PSMA-PET/CT as part of RT treatment planning.
Study: NCT04214600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Patients in the CBT intervention group will receive four educational sessions for 30-45 minutes on one to one basis every two weeks during patients' regular follow up visits. The visits will be scheduled depending on the patient's availability. The sessions will be delivered by a trained physician. The sessions will include:~Session 1: Dealing with thoughts of sadness and depression Session 2: Dealing with thoughts of anxiety and stress Session 3: Dealing with anger Session 4: Enhancement of coping and problem-solving skills
Study: NCT00842270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB1010
Description: 3 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB1010
Description: 4,5 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB1010
Description: 6 mg/kg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo to AB1010 dosages
Study: NCT03013660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Limited Financial Support
Description: Subjects randomized to this arm will be contacted to be informed that they are eligible to receive a weekly financial transfer to help them spend more time with their baby at the NICU. The intervention participants will be eligible to receive this transfer every 7 days, starting on the day of enrollment.
Study: NCT05316415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acemaşiran Music Group
Description: Agreeing to participate in the study Knowing Turkish and being literate Having been hospitalized for bed rest for at least 5 days. Having a gestational age of 28 to 36 weeks Being hospitalized due to at least one of the diagnoses including hypertensive diseases, diabetes mellitus, preterm labor, placenta previa, cervical insufficiency, or premature rupture of the membrane
Study: NCT01621113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalfampridine
Description: Dalfampridine 10 mg tablet, twice-daily, for 10 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet, twice daily, for 10 weeks.
Study: NCT03274960

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Griess,
Description: Experimental: Griess, Culture and antibiotic Griess reagents, sulfanilamide and NED added in urine sample for 20 minutes, urine culture using blood agar for 24 hours and treatment with antibiotic every trimester for up to 7 days.
Study: NCT03719170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PPI De-prescribing Program
Description: The PPI de-prescribing program includes alerts to clinical pharmacy specialists and primary care providers informing them of individual patients scheduled for upcoming primary care visits who meet criteria for PPI de-prescription; activation of clinical pharmacy specialists; education of primary care providers; and patient education.
Study: NCT02708719

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pulmonary rehabilitation
Description: Inpatient pulmonary rehabilitation has a duration of 3 weeks. This multimodal program consists of exercise training, breathing therapy, medical council, education and psychological support.
Study: NCT05025202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercise training
Description: A form of exercise involving static contraction against a wall, sustained for 2 minutes x4 sets per session. 3 sessions a week were required. The intensity was designed to achieve 95% of the participants maximum heart rate.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Isometric exercise training
Description: A form of exercise involving static contraction against a wall, sustained for 2 minutes x4 sets per session. 3 sessions a week were required. The intensity was designed to achieve 95% of the participants maximum heart rate.
Study: NCT00003657

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study: NCT03000608

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAN021 Placebo
Description: SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
Study: NCT02091648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I Can Cope Intervention
Description: Participants randomized to the I Can Cope condition will receive 6 face-to-face individualized sessions over a 2-month period. Each session will last 50 minutes and take place at the child's school either during approved times during the school day or as part of the after-school program. Sessions are psychoeducational and experiential and include opportunities for the child with asthma to: (1) learn about the pathophysiology of asthma; (2) understand the biological impact of stress on the body; (3) learn the relationship among thoughts, feelings, actions, and asthma; (4) acquire a set of coping skills to help deal with asthma-related and day-to-day stressors in their lives, and (5) receive training in biofeedback-assisted relaxation techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Education Intervention
Description: This group will receive the standard American Lung Association (ALA)Open Airways for Schools program. This program includes six 40-minute sessions covering the National Heart Lung and Blood Institute's recommendations for asthma education.
Study: NCT01633983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 7.5 mg per week p.o. escalating up to 15 mg per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delayed treatment
Description: Methotrexate 7.5 mg per week per os escalating to 15 mg per week
Study: NCT01600521

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A Natural Remedy for Rheumatoid Arthritis vs. Common Drugs
Description: The comparisons of the efficacy and safety of the following treatments for rheumatoid arthritis: paeoniflorin (PAE) + Cervus and Cucumis polypeptide injection (CCPI), methotrexate (MTX) + leflunomide (LEF), and MTX + LEF + CCPI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A Natural Remedy for Rheumatoid Arthritis vs. Common Drugs
Description: The comparisons of the efficacy and safety of the following treatments for rheumatoid arthritis: paeoniflorin (PAE) + Cervus and Cucumis polypeptide injection (CCPI), methotrexate (MTX) + leflunomide (LEF), and MTX + LEF + CCPI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A Natural Remedy for Rheumatoid Arthritis vs. Common Drugs
Description: The comparisons of the efficacy and safety of the following treatments for rheumatoid arthritis: paeoniflorin (PAE) + Cervus and Cucumis polypeptide injection (CCPI), methotrexate (MTX) + leflunomide (LEF), and MTX + LEF + CCPI.
Study: NCT03448120

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Six needled will be inserted in six already defined acupoints along the non-dominant upper limb for a period of 30 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Six needles will be inserted in six predefined points along the volunteers non-dominant biceps brachialis for 30 minutes.
Study: NCT02833532

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Volus/Powerfill
Description: Maximum: 22ml

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Volus/Powerfill
Description: Maximum: 22ml
Study: NCT00118755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 850 mg/m\^2 po bid on Days 1-14 of each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m\^2 IV on Day 1 of each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 7.5 mg/kg IV on Day 1 of each 3-week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: 1500 mg/m\^2 po bid on Days 1-7 of each 2-week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85 mg/m\^2 IV on Day 1 of each 2-week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: 5 mg/kg IV on Day 1 of each 2-week cycle
Study: NCT00686725

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study: NCT03237351

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluid therapy
Description: Conventional therapy group: conventional arterial blood pressure monitoring. Low value of PPV group and high value of PPV group:pulse pressure variation monitoring with arterial blood pressure monitoring.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluid therapy
Description: Conventional therapy group: conventional arterial blood pressure monitoring. Low value of PPV group and high value of PPV group:pulse pressure variation monitoring with arterial blood pressure monitoring.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluid therapy
Description: Conventional therapy group: conventional arterial blood pressure monitoring. Low value of PPV group and high value of PPV group:pulse pressure variation monitoring with arterial blood pressure monitoring.
Study: NCT00292162

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation
Description: isolation of the pulmonary veins with radiofrequency ablation (RFA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE inhibitor - ramipril, enalapril, captopril, perindopril, lisinopril
Description: Evidence based treatment for heart failure. Dose and type will depend on patient tolerability.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol
Description: Evidence based treatment for heart failure. Dose and type will depend on patient tolerance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aldosterone Antagonists - spironolactone
Description: Evidence based treatment for heart failure. Dose and type will depend on patient to treatment.
Study: NCT02445950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-aided phone wellness counselling
Description: The intervention provides phone wellness counselling with the help of web-based interventions, digital profiling and suggestion tool in occupational health.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phone wellness counselling
Description: The intervention provides phone wellness counseling in occupational health.
Study: NCT02118558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard prophylactic therapy
Description: administration of antibiotics before the first incision, keeping the surgery field sterile and performing several rinsing
Study: NCT02490553

Intervention type: OTHER
Intervention: heteroevaluation scale by a nurse or doctor

Intervention type: OTHER
Intervention: heteroevaluation scale by a nurse or doctor
Study: NCT01386788

Intervention type: OTHER
Intervention: There is no intervention planned (observational)
Description: No intervention foreseen